key: cord-0949668-e2cezk7j authors: Brod, Staley A. title: Review of approved NMO therapies based on mechanism of action, efficacy and long-term effects date: 2020-10-07 journal: Mult Scler Relat Disord DOI: 10.1016/j.msard.2020.102538 sha: 543c2eba0203596bb9a9735ee87cc07c3d5f70b5 doc_id: 949668 cord_uid: e2cezk7j Importance: Neuromyelitis optica (NMO - including NMO spectrum disorders [NMOSD]) is a devastating disease. Eighty-three percent of patients with transverse myelitic (TM) attacks and 67% of patients with optic neuritis (ON) attacks have no or a partial recovery. Observations: Up until recently, there was no proven agent to treat to prevent relapses. The neuro-immunological community had a dearth of indicated agents for NMOSD. We now have three agents indicated for the treatment of NMO including (eculizumab [Solaris®]), an anti-C5 complement inhibitor, satralizumab (ENSRYNG®), a monoclonal antibody against the IL-6 receptor (IL-6R) that blocks B cell antibody production and inebulzumab (Uplinza®), a monoclonal antibody that binds to the B-cell surface antigen CD19 with subsequent B and plasmablast cell lymphocytolysis with decreasing antibody production. Autologous hematopoietic stem cell bone marrow transplantation (AHSCBMT) has also been used. How do we sequence NMO therapies with the understanding of the acuteness and severity of the disease, the individual mechanism of action (MOA) and rapidity of onset of action, onset of efficacy and long-term safety of each agent? Conclusions and Relevance: We might suggest the following sequence – 1st line using eculizumab for rapid efficacy and stabilization without effect on the acquired immune system followed by satrilizumab (long term immunomodulation). Reserve inebilizumab (immunosuppressant) for breakthrough disease and salvage the severe with AHSCBMT. In NMO, control the complement, transition to modulation, and reserve suppression – and salvage the severe with AHSCBMT.  Neuromyelitis optica (NMO -including NMO spectrum disorders [NMOSD] ) is a devastating disease.  Up until recently, there was no proven agent to treat to prevent relapses.  We now have three agents indicated for the treatment of NMO  We might suggest the following sequence -1st line using eculizumab for rapid efficacy and stabilization without effect on the acquired immune system followed by satrilizumab (long term immunomodulation).  Reserve inebulizumab (immunosuppressant) for breakthrough disease and salvage the severe with AHSCBMT.  In NMO, control the complement, transition to modulation, and reserve suppressionand salvage the severe with AHSCBMT. NMOSD is a relapsing, inflammatory, autoimmune disorder 7 characterized in large part by attacks of optic neuritis (ON) and transverse myelitis (TM) causing blindness and paresis in many patients [8] [9] [10] . Attacks are unpredictable and tend to be severe (a 'neuro-immunological stroke') and recurrent 4, 9 annualized relapse reduction (ARR) 33 ! RTX re-administration has been monitored by the reappearance of CD27 memory B cells 34 . NMO activity has been correlated with B cell levels but not AQP4 levels in RTX treated patients 35 . A meta-analysis of 25 studies using RTX in NMO suggested a mean reduction of 0.79 in relapses and 0.64 points in EDSS 36 . Another metaanalysis suggested a 63% ARR 37 . We on the other hand have had variable results using RTX 38 . IV IgG, not useful in MS, has barely been studied 39 . Cyclophosphamide 40 and mitoxantrone have been evaluated in small studies 41, 42 but the latter's long-term (leukemogenic) side effect profile makes it a poor choice. MS therapies do not work -indeed they can make the disease worse including alemtuzumab 43 , natalizumab 44 , beta interferon 45, 46 and fingolimod 47 . Tocilizumab has also been used in NMOSD in small trials with modest efficacy 48, 49 . In contrast to the adaptive immune system and antigen-specific responses after antigen processing and generation of immune cells with memory in MS, NMO at its target is a disease of the innate immune system. The innate immune system is a nonspecific defense mechanism that comes into play immediately or within hours. These mechanisms include complement proteins in the blood [50] [51] [52] . NMO-IgG activates the complement system after IgG antibody molecules bind to the surface of the astrocyte. The self-amplifying, inflammatory, and destructive properties of the complement cascade make it essential that activated components be rapidly inactivated. Deactivation is achieved by specific inhibitor proteins in the blood or on the surface of host cells that terminate the cascade. These inhibitors are not present in the CNS. Therefore, complement fixation by NMO-IgG is unopposed once initiated. Anti-AQP4 antibodies fix compliment and begin a cascade of events to give rise to formation of the membrane attack complex (MAC) resulting in disruption of the astrocyte cell membranes 8, 53 . This damage can occur quite rapidly, perhaps within hours 54 . Once the rapid effect of complement fixation occurs during an NMO attack, there is unopposed and continual destruction. Indeed, it is unclear why it stops! Halting the acute ongoing destruction is an important therapeutic goal. The most effective interventions should prevent relapses but also have rapid anti-complement activity. Several pathophysiologic mechanisms are involved in the permanent CNS damage associated with NMOSD. While NMOSD is often referenced as an astrocytopathy driven by AQP4 autoantibodies, direct damage to oligodendrocytes and neurons also occurs as a result of several inflammatory mechanisms resulting from T and B cell activation. CD19+CD20-plasma cells produce AQP4 autoantibodies 55-58 inducing IL-6 and breaking down the BBB and endothelial cell function 59 .There is also a complement-independent cell-mediated cytotoxicity from NK and cytotoxic T cells 60 and IFN I and Th17 cells 61 . B cell depletion in autoimmune settings may derive its therapeutic effect on T follicular helper cells (Tfh) that require B cells in tertiary lymphoid structures 58 . Both B and T cells produce inflammatory cytokines 14,62 toxic to neurons and oligodendroglial cells 57 . The neuro-immunological community will have gone from a dearth of indicated agents for NMOSD to multiple indicated agents over a relatively short period of time. As MS has been transformed from a diagnostic dilemma to a therapeutic dilemma (J. Dunn, Stanford), so NMO may well become a therapeutic dilemma too. The initial and subsequent interventions using indicated agents may depend on the mechanism of action (MOA), rapidity of the onset of action (OOA), duration of efficacy and long-term safety. Frequency of administration, route of administration and monitoring will also assuredly play a role for the patient and the clinician. Let's review the available clinical data on the present agents and potential future approaches. weeks and terminated after a prespecified number of relapses. We might consider eculizumab an immunomodulator of the innate immune system without effect on acquired immunity notwithstanding precautionary prophylaxis vaccination for Neisseria sps. Ravulizumab, a second generation to eculizumab with a four aminoacid change, has a prolonged terminal half-life with eight week dosing intervals, is currently in clinical trials 64 . Tocilizumab (RoActemra ® ; Chugai/Roche), a precursor to an upcoming agent for NMOSD, is a first-in-class humanized monoclonal antibody that binds specifically to both sIL-6R and mIL-6R and inhibits IL-6R-mediated signaling and specifically blocks IL-6 activity 65 . Tocilizumab was approved for patients with moderate to severe rheumatoid arthritis (RA) unresponsive to available disease modifying anti-rheumatic drugs (DMARD) [65] [66] [67] [68] [69] [70] . Parenteral tocilizumab, as a repurposed from RA DMARD, can also be effective in other inflammatory diseases including neuromyelitis optica (NMO) by reducing anti-AQP4 autoantibodies 71 . Tocilizumab has also been used in NMOSD in small trials with modest efficacy 48, 49 . and was maintained for 3+ years. The SakuraStar satrilizumab monotherapy for relapse prevention trial showed a 25% relapse rate at 48 weeks for active treatment 73 . These latter data also suggest a delayed onset of action. The authors (SakuraSky) state that longer and larger trials are necessary to determine the efficacy and durability of satralizumab. A recently approved agent in the US is inebilizumab (Uplinza ® ), a humanised, affinity- without reference to attacks in the placebo or active arms. There is a falloff at 6 months with attacks in 13% of patients and 15% at 12 months according to extension data 75 . We might assume a plateau at 12 months with extension data. A concern with this agent is its similarity to ocrelizumab, the fully humanized anti-CD20 mAb derived from rituximab, devised initially to treat lymphoma, repurposed to treat autoimmune disorders including MS and used off-label for the treatment of NMOSD. As it stands, there are at least 7 PML (confounded) cases and 1 unconfounded PML case associated with its use. Ocrelizumab was also associated with an increased incidence of breast cancer (increased, but statistically insignificant) particularly in the PPMS clinical trial. Ocrelizumab is immunosuppressive because it causes a B cell lymphopenia along with a definable incidence of PML. Ocrelizumab requires continual administration to maintain its effectiveness and has had a 5.5% mortality from confirmed COVID-19 infections 76 . Interventional strategies that target pathogenic AQP4 auto-antibodies should consider their ability to leave previously established humoral immunity intact 77 . Protective antibodies to vaccine antigens (i.e., influenza, tetanus, measles, mumps, rubella, and polio) are produced by both CD19+ and CD19-subsets and long-lived antibody producing plasma cells. Differences in CD expression occur throughout B cell maturation and within tissue-localized late-stage B cells [77] [78] [79] . Therefore, targeting CD19+ B cells may leave some established humoral immunity relatively unscathed. There is a 4th potential therapeutic option in NMOSD. Autologous hematopoietic stem cell bone marrow transplantation (AHSCBMT) is an example of immune reconstitution therapy (IRT) within autoimmunity. AHSCBMT is associated with profound qualitative immunological changes and the resetting of the immune system (i.e., immunostat) in patients with MS 80, 81 . AHSCBMT has been utilized in the treatment of advanced MS over long periods and reviewed in recent meta-analyses 82 . AHSCBMT has been studied in NMO also albeit in smaller numbers. (quashing, stamping out) and impedes immunosurveillance. Inebilizumab is similar to ocrelizumab but depletes an even wider range of lymphocytes from the B-cell lineage. Ocrelizumab was also associated with an increased incidence of breast cancer (increased, but statistically insignificant) particularly in the primary progressive MS OROTORIO clinical trial 92 . Inebilizumab targets a broader B cell community with potential greater effects on gamma globulins, B cell and plasmablast lymphocytotoxicity with a potential for decreased cancer surveillance similar to ocrelizumab 93 with at least 7 PML (confounded) cases and 1 unconfounded PML case in MS. There is also a 6% incidence of hypo-gammaglobuliemia 94 with inebilizumab. Therefore, inebilizumab appears to be immunosuppressive because it causes a B cell lymphopenia along with a potential for PML and requires continual administration to maintain its effectiveness. Assuming the availability of all the agents mentioned above, how do we sequence NMO therapies with the understanding of the acuteness and severity of the disease, the MOA, rapidity of onset of action and long term safety of these four interventions? Eculizumab acts where the rubber meets the road and has long term (4 year) data with continued high efficacy so it invites itself as initial therapy. Because eculizumab acts rapidly it could be used as an acute intervention during attacks. Its draw backs are frequency of administration and potential cost. Satralizumab may suffer from initial (SukuraSky 11% [adjudicated] -31% [clinical]; SukuraStar 25%) relapse incidence at 48 weeks suggesting a delayed onset of action after intervention. Its advantages are relative ease of administration (sq) and its (in)frequency of dosing. Inebilizumab's advantage is its MOA directed at antibody producing cells (B cells and plasmablasts) but suffers a delay in onset of activity (13% incidence of time to first relapse at 24 weeks) and our present inability to forecast its plateau in relapse prevention beyond 24 weeks and continued efficacy and safety absent long term follow-up data. We might suggest the following sequence -1st line using eculizumab for rapid efficacy and stabilization followed by satrilizumab (see figure below). How long do you keep patients on eculizumab understanding the dosing and cost before you segue to satrilizumab? That is unclear. The advantages of these two agents is that there is no effect on acquired immunity (by eculizumab) and immunomodulation without immunosuppression (by satrilizumab) of the Starting initially with inebilizumab and transitioning to satrilizumab would require concomitant therapy for extended periods of time as above. This transition may not be rational since satrilizumab requires B cells for its effectiveness despite the potential shift from an immunosuppressant to an immunomodulator more compatible for long term therapy. Could we make a case for initial and continual satrilizumab treatment with convenient selfadministration and immune modulation? Perhaps but any breakthrough disease would precipitate a retreat to potentially more efficacious agents so why start there and escalate? How would we include AHSCBMT as a therapeutic option? AHSCBMT could be used as salvage therapy for severe breakthrough disease after sequencing of NMO-DMTs but that risks significant preceding disability. AHSCBMT could also be used as an induction therapy for severe initial presentations providing a safe segue for the initiation of long-term immunomodulation. Is there a role for rituximab in NMO therapy despite the lack of class I evidence from randomized placebo controlled clinical trials 30, 33 ? If NMO patients are stable (relapse free) on off-label RTX, how long should they remain stable (relapse free) in order not to switch to agents proven to be effective in relapse prevention? If 90% of relapses occur within 5 years 2,4 perhaps 5 years relapse free on RTX or another off-label agent may suffice as evidence for disease control without the need for transition to an approved therapy. Neuromyelitis optica (NMO -including NMO spectrum disorders [NMOSD] ) is an interesting, devastating, and soon-to-be therapeutic challenging disease using approved (and off label) interventions. The expansion of the NMOSD pharmacopeia offers unique opportunities to prevent and control a neurological entity heretofore managed without solid clinical evidence. The MOA, onset of activity and long-term efficacy in clinical trials can help direct therapeutic sequencing. Transitioning from the most efficacious agent(s) without effects on acquired immunity to immunomodulators for long term treatment might be the best route. Immunosuppressive therapies could be used as a back-up as necessary. AHSCBMT could be used to reconstitute the immune system after severe attacks. In NMO, control the complement, transition to modulation, and reserve suppressionand salvage the severe with AHSCBMT. The author has no financial interest in this manuscript. SAB: Consulting agreements or speaker for Acorda, Avanir, Bayer HealthCare, EMD Serono, Genzyme, Pfizer, Mallinckrodt, Teva Neurosciences, Alexion and Vielo Bio and research or contractual support from the Clayton Foundation for Research, EMD Serono, Pfizer, Genzyme, Questcor and Quasi Foundation. The advantages and disadvantages of each of these transitions are outlined Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients Evaluation of comorbidities and health care resource use among patients with highly active neuromyelitis optica Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan Mortality in neuromyelitis optica is strongly associated with African ancestry Neuromyelitis optica spectrum disorder: Patient experience and quality of life Nationwide prevalence and incidence study of neuromyelitis optica spectrum disorder in Denmark Long-term disability in neuromyelitis optica spectrum disorder with a history of myelitis is associated with age at onset, delay in diagnosis/preventive treatment, MRI lesion length and presence of symptomatic brain lesions. Multiple sclerosis and related disorders The clinical course of neuromyelitis optica (Devic's syndrome) The spectrum of neuromyelitis optica Autoimmune AQP4 channelopathies and neuromyelitis optica spectrum disorders Idiopathic aquaporin-4 antibody negative longitudinally extensive transverse myelitis Neuromyelitis optica: a positive appraisal of seronegative cases Update on biomarkers in neuromyelitis optica MOG antibody disease: A review of MOG antibody seropositive neuromyelitis optica spectrum disorder. Multiple sclerosis and related disorders The impact of 2015 neuromyelitis optica spectrum disorders criteria on diagnostic rates Epidemiology of aquaporin-4 autoimmunity and neuromyelitis optica spectrum Presence of aquaporin-4 and muscarinic receptors in astrocytes and ependymal cells in rat brain: a clue to a common function? Aquaporins and water homeostasis in the central nervous system The aquaporin-4 water channel as a potential drug target in neurological disorders Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression Corticosteroids or ACTH for acute exacerbations in multiple sclerosis Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica Apheresis therapies for NMOSD attacks: A retrospective study of 207 therapeutic interventions Role of intravenous immunoglobulin in the treatment of acute relapses of neuromyelitis optica: experience in 10 patients Idiopathic transverse myelitis: corticosteroids, plasma exchange, or cyclophosphamide Neuromyelitis optica treatment: analysis of 36 patients Devic's neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients An open label study of the effects of rituximab in neuromyelitis optica Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis Rituximab as first-line therapy in neuromyelitis optica: efficiency and tolerability A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab Efficacy and Safety of Rituximab Therapy in Neuromyelitis Optica Spectrum Disorders: A Systematic Review and Meta-analysis Effectiveness of rituximab in neuromyelitis optica: a metaanalysis Variable results after rituximab in neuromyelitis optica The effect of intravenous immunoglobulin on neuromyelitis optica Efficacy of intravenous cyclophosphamide therapy for neuromyelitis optica spectrum disorder Efficacy and safety of mitoxantrone in patients with highly relapsing neuromyelitis optica Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease) Massive CNS monocytic infiltration at autopsy in an alemtuzumab-treated patient with NMO Failure of natalizumab to prevent relapses in neuromyelitis optica IFNbeta-1b may severely exacerbate Japanese optic-spinal MS in neuromyelitis optica spectrum Immunosuppressive therapy is more effective than interferon in neuromyelitis optica Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder Long-term Therapy With Interleukin 6 Receptor Blockade in Highly Active Neuromyelitis Optica Spectrum Disorder Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study Complement and its role in innate and adaptive immune responses STEC-HUS, atypical HUS and TTP are all diseases of complement activation Thrombosis in paroxysmal nocturnal hemoglobinuria Neuromyelitis optica spectrum disorder diagnostic criteria: Sensitivity and specificity are both important In vivo imaging reveals rapid astrocyte depletion and axon damage in a model of neuromyelitis optica-related pathology The Immunology of Neuromyelitis Optica-Current Knowledge, Clinical Implications, Controversies and Future Perspectives Mechanisms for lesion localization in neuromyelitis optica spectrum disorders B lymphocytes in neuromyelitis optica T Cell/B Cell Collaboration and Autoimmunity: An Intimate Relationship Effects of neuromyelitis optica-IgG at the blood-brain barrier in vitro Neuromyelitis optica: aquaporin-4 based pathogenesis mechanisms and new therapies Transcriptomics and proteomics reveal a cooperation between interferon and T-helper 17 cells in neuromyelitis optica CSF cytokine profile in MOG-IgG+ neurological disease is similar to AQP4-IgG+ NMOSD but distinct from MS: a crosssectional study and potential therapeutic implications Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder Emerging drugs for the treatment of neuromyelitis optica Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease Clinical study of tocilizumab in children with systemic-onset juvenile idiopathic arthritis Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial Humanized antihuman IL-6 receptor antibody, tocilizumab. Handbook of experimental pharmacology Tocilizumab: blockade of interleukin-6 signaling pathway as a therapeutic strategy for inflammatory disorders Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder Efficacy of satralizumab as monotherapy in pre-specified subgroups of SAkuraStar, a double-blind placebo-controlled phase 3 clinical study in patients with neuromyelitis optica spectrum disorder (NMOSD) Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind The N-MOmentum study -a randomized, placebocontrolled, double-blind trial of inebilizumab for neuromyelitis optica spectrum disorder: randomized controlled period and open-label extension results. 5th annual Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum B cell-based therapies in CNS autoimmunity: differentiating CD19 and CD20 as therapeutic targets. Therapeutic advances in neurological disorders Anti-B-Cell Therapies in Autoimmune Neurological Diseases: Rationale and Efficacy Trials Condition-dependent generation of aquaporin-4 antibodies from circulating B cells in neuromyelitis optica Hematopoietic stem cell therapy for multiple sclerosis: top 10 lessons learned Autologous haematopoietic stem-cell transplantation in multiple sclerosis Autologous hematopoietic stem cell transplantation in multiple sclerosis: A meta-analysis Resolution of aquaporin-4 antibodies in a woman with neuromyelitis optica treated with human autologous stem cell transplant A preliminary result of treatment of neuromyelitis optica with autologous peripheral hematopoietic stem cell transplantation Autologous hematopoietic stem cell transplantation in neuromyelitis optica: a registry study of the EBMT Autoimmune Diseases Working Party Restoring immune tolerance in neuromyelitis optica: Part I Restoring immune tolerance in neuromyelitis optica: Part II Autologous haematopoietic stem cell transplantation for secondary progressive multiple sclerosis: an exploratory costeffectiveness analysis Regenerating Immunotolerance in Multiple Sclerosis with Autologous Hematopoietic Stem Cell Transplant In MS: Immunosuppression is passe. Multiple sclerosis and related disorders Opportunistic infections and biologic therapies in immune-mediated inflammatory diseases: consensus recommendations for infection reporting during clinical trials and postmarketing surveillance Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid cells surface antigens [I]: CD19, CD20 and CD52)